Novel Biological and Pharmacological Interventions for Obesity Prevention

Background

Novo Nordisk's Transformational Prevention Unit (TPU) is seeking data-backed opportunities to develop solutions for predicting and pre-empting obesity risk. The company aims to create novel, multi-sector partnerships to deliver impactful solutions across four inter-related product categories.

Approaches of interest:

• Substances with biological effects on weight management and metabolic health
• Solutions for preventing obesity-related cardiometabolic disorders
• All modalities, including medical devices for therapeutic compound delivery
• All delivery routes, with priority for oral solutions
• All mechanisms of action, including those affecting appetite, energy expenditure, and novel MoAs
   

Out of scope:

• Behavioral approaches to weight management
• Medical devices used only for monitoring weight and cardiometabolic health
   

Developmental stage of interest:

Opportunities from preclinical research onwards, with priority given to research with clinical validation. Preclinical research should have in vivo validation, with data demonstrating safety preferred.

Email Cameron Sargent, CTTC Licensing Officer for Biotechnology and Health Science Licensing, at Cameron.Sargent@Vanderbilt.edu for more information.